Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls

International Journal of Psychophysiology

Volumn 88, Issue 2, 2013, Pages 149-156

  Van Tricht, Mirjam J ^a   Harmsen, Emma C ^a   Koelman, Johannes H T M ^a   Bour, Lo J ^a   van Amelsvoort, Thérèse A ^b   Linszen, Don H ^a   de Haan, Lieuwe ^a   Nieman, Dorien H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cannabis; Event related potentials; Information processing; Psychosis

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; LATENT PERIOD; MALE; MENTAL DISEASE; POSITIVE SYNDROME; PSYCHOSIS;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; PSYCHOTIC DISORDERS; REACTION TIME; RISK FACTORS; YOUNG ADULT;

EID: 84878107519     PISSN: 01678760     EISSN: 18727697     Source Type: Journal    
DOI: 10.1016/j.ijpsycho.2013.03.012     Document Type: Article

References (67)

1. Atkinson R.J., Michie P.T., Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry 2012, 71:98-104. 10.1016/j.biopsych.2011.08.023.
2. Bhattacharyya S., Crippa J.A., Allen P., Martin-Santos R., Borgwardt S., Fusar-Poli P., Rubia K., Kambeitz J., O'Carroll C., Seal M.L., Giampietro V., Brammer M., Zuardi A.W., Atakan Z., McGuire P.K. Induction of psychosis by {Delta}9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 2012, 69:27-36.
3. Böcker K.B.E., Gerritsen J., Hunault C.C., Kruidenier M., Mensinga T., Kenemans J.L. Cannabis with high [Delta]9-THC contents affects perception and visual selective attention acutely: an event-related potential study. Pharmacology Biochemistry and Behavior 2010, 96:67-74.
4. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 2004, 70:315-329.
5. Bramon E., Shaikh M., Broome M., Lappin J., Bergé D., Day F., Woolley J., Tabraham P., Madre M., Johns L., Howes O., Valmaggia L., Pérez V., Sham P., Murray R.M., McGuire P. Abnormal P300 in people with high risk of developing psychosis. NeuroImage 2008, 41:553-560.
6. Brockhaus-Dumke A., Schultze-Lutter F., Mueller R., Tendolkar I., Bechdolf A., Pukrop R., Klosterkoetter J., Ruhrmann S. Sensory Gating in Schizophrenia: P50 and N100 Gating in Antipsychotic-Free Subjects at Risk, First-Episode, and Chronic Patients. Biol Psychiatry 2008, 64:376-384.
7. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
8. 9-THC in humans. 2012.
9. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
10. Dean B., Bradbury R., Copolov D.L. Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biological Psychiatry 2003, 53:585-592.
11. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
12. Dissanayake D.W., Mason R., Marsden C.A. Sensory gating, cannabinoids and schizophrenia. Neuropharmacology 2012, 12:66-77.
13. Evans D.E., Park J.Y., Maxfield N., Drobes D.J. Neurocognitive variation in smoking behavior and withdrawal: genetic and affective moderators. Genes, Brain, and Behavior 2009, 8:86-96.
14. Ford J.M., Mathalon D.H., Kalba S., Marsh L., Pfefferbaum A. N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike features. Biological Psychiatry 2001, 49:848-860.
15. Frommann I., Brinkmeyer J., Ruhrmann S., Hack E., Brockhaus-Dumke A., Bechdolf A., Wölwer W., Klosterkötter J., Maier W., Wagner M. Auditory P300 in individuals clinically at risk for psychosis. International Journal of Psychophysiology 2008, 70:192-205.
16. Gratton G., Coles M., Donchin E. A new method for off-line removal of ocular artifact. Electroencephalography and Clinical Neurophysiology 1982, 55:468-484.
17. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. International Review of Neurobiology 2007, 78:1-39.
18. Haenschel C., Bittner R.A., Haertling F., Rotarska-Jagiela A., Maurer K., Singer W., Linden D.E. Contribution of impaired early-stage visual processing to working memory dysfunction in adolescents with schizophrenia: a study with event-related potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 2007, 64:1229-1240.
19. Hall W., Babor T.F. Cannabis use and public health: assessing the burden. Addiction 2000, 95:485-490.
20. Hermens D.F., Ward P.B., Hodge M.A., Kaur M., Naismith S.L., Hickie I.B. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:822-829.
21. Hirvonen J., Goodwin R.S., Li C.T., Terry G.E., Zoghbi S.S., Morse C., Pike V.W., Volkow N.D., Huestis M.A., Innis R.B. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry 2012, 17:642-649.
22. Jahshan C., Wynn J.K., Mathis K.I., Altshuler L.L., Glahn D.C., Green M.F. Cross-diagnostic comparison of duration mismatch negativity and P3a in bipolar disorder and schizophrenia. Bipolar Disorders 2012, 14:239-248.
23. Johns A. Psychiatric effects of cannabis. The British Journal of Psychiatry 2001, 178:116-122.
24. Johnson J.P., Muhleman D., MacMurray J., Gade R., Verde R., Ask M., Kelley J., Comings D.E. Association between the cannabinioid receptor gene (CNR1) and the P300-event related potential. Molecular Psychiatry 1997, 2:169-171.
25. Juckel G., Roser P., Nadulski T., Stadelmann A.M., Gallinat J. Acute effects of [Delta]9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophrenia Research 2007, 97:109-117.
26. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. The American Journal of Psychiatry 2003, 160:13-23.
27. Kempel P., Lampe K., Parnefjord R., Hennig J., Kunert H.J. Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology 2003, 48:95-101.
28. Kessler R.C., Ustun T.B. The world mental health survey initiative version of the composite international diagnostic interview. International Journal of Methods in Psychiatric Research 2004, 13:93-121.
29. Kirihara K., Araki T., Uetsuki M., Yamasue H., Hata A., Rogers M.A., Iwanami A., Kasai K. Association study between auditory P3a/P3b event-related potentials and thought disorder in schizophrenia. Brain Imaging and Behavior 2009, 3:277-283.
30. Korver N., Nieman D.H., Becker H.E., van de Fliert J.R., Dingemans P.H., de Haan L., Spiering M., Schmitz N., Linszen D.H. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. The Australian and New Zealand Journal of Psychiatry 2010, 44:230-236.
31. Laurens K.R., Kiehl K.A., Ngan E.T., Liddle P.F. Attention orienting dysfunction during salient novel stimulus processing in schizophrenia. Schizophr Res 2005, 15:159-171.
32. Linszen D., van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Current Opinion in Psychiatry 2007, 20.
33. Meier M.H., Caspi A., Ambler A., Harrington H., Houts R., Keefe R.S.E., McDonald K., Ward A., Poulton R., Moffitt T.E. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E2657-E2664.
34. Meijer J.H., Dekker N., Koeter M.W., Quee P.J., van Beveren N.J.M., Meijer C.J. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychological Medicine 2012, 42:705-716.
35. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., Woods S.W. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 2003, 29:703-715.
36. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet 2007, 370:319-328.
37. Näätänen R., Michie P.T. Early selective-attention effects on the evoked potential: A critical review and reinterpretation Biol Psychol 1979, 8:81-136.
38. O'Donnell B.F., Vohs J.L., Hetrick W.P., Carroll C.A., Shekhar A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. International Journal of Psychophysiology 2004, 53:45-55.
39. Pesa N., Hermens D.F., Battisti R.A., Kaur M., Hickie I.B., Solowij N. Delayed preattentional functioning in early psychosis patients with cannabis use. Psychopharmacology 2012, 222:507-518.
40. Polich J. Updating P300: an integrative theory of P3a and P3b. Clinical Neurophysiology 2007, 118:2128-2148.
41. Potts G.F., Hirayasu Y., O'Donnell B.F., Shenton M.E., McCarley R.W. High-density recording and topographic analysis of the auditory oddball event-related potential in patients with schizophrenia. Biol Psychiatry 1998, 44:982-989.
42. Rentzsch J., Buntebart E., Stadelmeier A., Gallinat J., Jockers-Scherübl M.C. Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophrenia Research 2011, 130:222-227.
43. Rentzsch J., Penzhorn A., Kernbichler K., Plöckl D., Gómez-Carrillo de Castro A., Gallinat J., Jockers-Scherübl M.C. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp Neurol. 2007, 205:241-249. http://www.ncbi.nlm.nih.gov/pubmed/17368620.
44. Rissling A.J., Braff D.L., Swerdlow N.R., Hellemann G., Rassovsky Y., Sprock J., Pela M., Light G.A. Disentangling early sensory information processing deficits in schizophrenia. Clinical Neurophysiology 2012, 123:1942-1949.
45. Roser P., Juckel G., Rentzsch J., Nadulski T., Gallinat J., Stadelmann A.M. Effects of acute oral [Delta]9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. European Neuropsychopharmacology 2008, 18:569-577.
46. Salisbury D.F., Collins K.C., McCarley R.W. Reductions in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia. Schizophrenia Bulletin 2010, 36:991-1000.
47. Salisbury D.F., O'Donnell B.F., McCarley R.W., Shenton M.E., Benavage A. The N2 event-related potential reflects attention deficit in schizophrenia. Biological Psychology 1994, 39:1-13.
48. Schmand B.A., Bakker D., Saan R., Louman J. The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschrift voor Gerontologie en Geriatrie 1991, 22:15-19.
49. Scholes-Balog K.E., Martin-Iverson M.T. Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. Hum Psychopharmacol 2011, 26:373-385.
50. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. Journal of Psychiatry & Neuroscience 2007, 32:30-52.
51. Solowij N., Michie P.T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry 1995, 37:731-739.
52. Spitzer R.L., Williams J.B., Gibber M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Archives of General Psychiatry 1992, 49:624-629.
53. Squires N.K., Squires K.C., Hillyard S.A. Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroencephalography and Clinical Neurophysiology 1975, 38:387-401.
54. Stadelmann A.M., Juckel G., Arning L., Gallinat J., Epplen J.T., Roser P. Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neuroscience Letters 2011, 496:60-64.
55. Theunissen E.L., Kauert G.F., Toennes S.W., Moeller M.R., Sambeth A., Blanchard M.M., Ramaekers J.G. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology 2012, 220:341-350.
56. Turetsky B.I., Colbath E.A., Gur R.E. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biological Psychiatry 1998, 43:84-96.
57. Turetsky B.I., Bilker W.B., Siegel S.J., Kohler C.G., Gur R.E. Profile of auditory information-processing deficits in schizophrenia. P3a/P3b abnormalities were associated with avolition, attentional disturbances and delusions. Psychiatry Research 2009, 30:127-137.
58. Van der Meer F., Velthorst E., Meijer C.J., Machielsen M.W., de Haan L. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Current Pharmaceutical Design 2012, 18:5036-5044.
59. van der Stelt O., Lieberman J.A., Belger A. Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophrenia Research 2005, 77:309-320.
60. van Tricht M.J., Nieman D.H., Koelman J.T.H.M., van der Meer J.N., Bour L.J., de Haan L., Linszen D. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biological Psychiatry 2010, 68:642-648.
61. van Tricht M.J., Nieman D.H., Koelman J.H., Mensink A.J., Bour L.J., vanderMeer J.N., vanAmelsvoort T.A., Linszen D.H., deHaan L. Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. The World Journal of Biological Psychiatry 2012, (Epub ahead of print) http://www.ncbi.nlm.nih.gov/pubmed/22730901.
62. van Winkel R., van Beveren N.J., Simons C. Genetic Risk and Outcome of Psychosis (GROUP) Investigators. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 2011, 36:2529-2537.
63. World Health Organisation Composite International Diagnostic Interview (CIDI). a) CIDI-interview (version 1.0), b) CIDI-user manual, c) CIDI-training manual d) CIDI-computer programs 1990, World Health Organisation, Geneva.
64. Yuan J., He Y., Qinglin Z., Chen A., Li H. Gender differences in behavioral inhibitory control: ERP evidence from a two-choice oddball task. Psychophysiology 2008, 45:986-993.
65. Yücel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 2012, 38:316-330.
66. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., Phillips L., McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophrenia Bulletin 2007, 33:673-681.
67. Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28:355-360.